Previous close | 120.60 |
Open | 121.00 |
Bid | 122.80 x 0 |
Ask | 122.80 x 0 |
Day's range | 121.00 - 123.00 |
52-week range | 91.00 - 124.40 |
Volume | |
Avg. volume | 982 |
Market cap | 311.563B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | 146.43 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.84 (2.31%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
RAHWAY, N.J., April 25, 2024--Merck Announces First-Quarter 2024 Financial Results
RAHWAY, N.J., April 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%).
BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer